Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163435 | 0.83 | MTNR1A (0.40) | CYP2D6HTR1AMTNR1AMTNR1BHTR2A | |
| SCHEMBL1163237 | 0.78 | ABCB1 (0.34) | ABCB1ABCG2HTR1ATDP1MAPT | |
| SCHEMBL1164344 | 0.71 | HTR1A (0.48) | CYP2D6HTR1AMTNR1AMTNR1BHTR6 | |
| SCHEMBL12595701 | 0.67 | MTNR1A (0.37) | MTNR1AMTNR1B | |
| SCHEMBL4395931 | 0.67 | HTR2A (0.57) | HTR1AHTR6HTR2A | |
| SCHEMBL1163214 | 0.66 | HTR2A (0.46) | HTR1AMEN1MAPTKMT2AHTR2A | |
| SCHEMBL1163371 | 0.65 | TAAR1 (0.38) | ABCB1ABCG2HTR1AMEN1KMT2A | |
| SCHEMBL1163475 | 0.64 | KDM4E (0.40) | TDP1MEN1MAPTKMT2AMTNR1A | |
| SCHEMBL24244161 | 0.63 | TDP1 (0.68) | HTR1ATDP1HTR2A | |
| SCHEMBL5387311 | 0.63 | HTR1A (0.48) | CYP2D6HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| EP-2464227-A1 | COMPOUNDS AND METHODS OF USE THEREOF | Galenea Corporation (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| WO-2011019738-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019738-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | CYP2D6 126/4885ABCB1 526/4885ABCG2 32/4885 |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | CYP2D6 126/4885ABCB1 526/4885ABCG2 32/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | CYP2D6 126/4885ABCB1 526/4885ABCG2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.